CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

Autor: Sabbah M; Hematology Department, Pitie-Salpetriere Hospital, 75013 Paris, France., Jondreville L; Hematology Department, Pitie-Salpetriere Hospital, 75013 Paris, France., Lacan C; Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Inserm U1135, CNRS ERL 8255, 75013 Paris, France., Norol F; Hematology Department, Pitie-Salpetriere Hospital, 75013 Paris, France., Vieillard V; Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Inserm U1135, CNRS ERL 8255, 75013 Paris, France., Roos-Weil D; Hematology Department, Pitie-Salpetriere Hospital, 75013 Paris, France., Nguyen S; Hematology Department, Pitie-Salpetriere Hospital, 75013 Paris, France.; Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Inserm U1135, CNRS ERL 8255, 75013 Paris, France.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Aug 08; Vol. 14 (15). Date of Electronic Publication: 2022 Aug 08.
DOI: 10.3390/cancers14153839
Abstrakt: Immunotherapy with chimeric antigen receptor-engineered T cells (CAR-T) has revolutionized the treatment landscape of relapsed/refractory B-cell malignancies. Nonetheless, the use of autologous T cells has certain limitations, including the variable quality and quantity of collected effector T cells, extended time of cell processing, limited number of available CAR cells, toxicities, and a high cost. Thanks to their powerful cytotoxic capabilities, with proven antitumor effects in both haploidentical hematopoietic stem cell transplantation and adoptive cell therapy against solid tumors and hematological malignancies, Natural Killer cells could be a promising alternative. Different sources of NK cells can be used, including cellular lines, cord blood, peripheral blood, and induced pluripotent stem cells. Their biggest advantage is the possibility of using them in an allogeneic context without major toxic side effects. However, the majority of the reports on CAR-NK cells concern preclinical or early clinical trials. Indeed, NK cells might be more difficult to engineer, and the optimization and standardization of expansion and transfection protocols need to be defined. Furthermore, their short persistence after infusion is also a major setback. However, with recent advances in manufacturing engineered CAR-NK cells exploiting their cytolytic capacities, antibody-dependent cellular cytotoxicity (ADCC), and cytokine production, "off-the-shelf" allogeneic CAR-NK cells can provide a great potential in cancer treatments.
Competing Interests: The authors declare no conflicts of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje